Applied DNA Q3 revenue down to $2.9M; net loss widens to $3.1M; acquires Spindle Biotech

BNB PLUS CORP.

2023-Q3 EPS reported -$0.49 revenue$12,587,707

Revenue $2.9M vs $4.3M YoY; decline driven by COVID-19 testing drop and CUNY contract wind-down.
Net loss $3.1M vs $1.1M YoY; operating loss flat at $2.9M; gross margin improved to 44%.
Cash $10.8M at June 30, down from $12.3M at March 31; Adjusted EBITDA -$2.1M.
Acquired Spindle Biotech post-quarter; launched Linea IVT platform for mRNA production.
NYSDOH PGx diagnostic approval pending; added new CertainT customers for supply chain traceability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BNB PLUS CORP. reported third quarter of fiscal 2023 ended June 30, 2023 results: revenue approximately $2.9 million, net income $3.1 million.

Period: third quarter of fiscal 2023 ended June 30, 2023
Revenue: approximately $2.9 million
Net income: $3.1 million
Result: reported results

Exact text from the filing

potential for cotton taggant orders and the initiation of large supply chain customers.” Summary Third Quarter Fiscal 2023 Financial Results: · Total revenues were approximately $2.9 million for the three-month period June 30, 2023, compared to $4.3 million for the same period in the prior fiscal year. The decrease in revenue of approximately $1.4 million was due to

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-23-089781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.